Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.

Alexey V SamtsovAndrey L BakulevVladislav R KhairutdinovMuza M KokhanTat'yana V KorotaevaIskander K MinullinOlga A VylegzhaninaValery V DubenskiyBulat V KhalilovAlkes A KhotkoOlga S ZykovaIrina V ChumachenkoAlexander M LukyanovAntonina V ArtemevaPolina P Pukhtinskaia

Published in: PloS one (2022)

Obtained data demonstrate that BCD-057 and iADA are highly similar in clinical efficacy, pharmacokinetics, safety, and immunogenicity in patients with moderate to severe plaque psoriasis.

Keyphrases

electronic health record
high intensity
early onset
big data
rheumatoid arthritis
coronary artery disease
atopic dermatitis
drug induced
juvenile idiopathic arthritis
artificial intelligence
deep learning